APA (7th ed.) Citation
(2026). Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study. Journal of Asthma and Allergy.
Chicago Style (17th ed.) Citation
"Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study." Journal of Asthma and Allergy 2026.
MLA (9th ed.) Citation
"Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study." Journal of Asthma and Allergy, 2026.
Warning: These citations may not always be 100% accurate.